Section1= Chembox Identifiers
Section2= Chembox Properties
Section3= Chembox Hazards
Laquinimod is an experimental
immunomodulatordeveloped by Active Biotechand Teva. It is currently investigated as an oral treatment of multiple sclerosis(MS).
Laquimod is the successor of Active Biotech's failed experimental immunomodulator
linomide. [cite journal |author=Tan IL, Lycklama à Nijeholt GJ, Polman CH et al |title=Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials |journal=Mult Scler |volume=6 |issue=2 |pages=99–104 |year=2000 |month=April |pmid=10773855]
The compound has been investigated in two Phase II trials using successive magnetic resonance scans (MRI). Laquinimod seems to be able to reduce the MS disease activity on MRI.cite journal |author=Comi G, Pulizzi A, Rovaris M, "et al" |title=Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study |journal=Lancet |volume=371 |issue=9630 |pages=2085–92 |year=2008 |month=June |pmid=18572078 |doi=10.1016/S0140-6736(08)60918-6] cite journal |author=Polman C, Barkhof F, Sandberg-Wollheim M et al |title=Treatment with laquinimod reduces development of active MRI lesions in relapsing MS |journal=Neurology |volume=64 |issue=6 |pages=987–91 |year=2005 |month=March |pmid=15781813 |doi=10.1212/01.WNL.0000154520.48391.69] However, the response to a given dose was discrepant between both studies. [cite journal |author=Keegan BM, Weinshenker BG |title=Laquinimod, a new oral drug for multiple sclerosis |journal=Lancet |volume=371 |issue=9630 |pages=2059–60 |year=2008 |month=June |pmid=18572062 |doi=10.1016/S0140-6736(08)60894-6]
The Phase III activities have been starting in 2008
* [http://clinicaltrials.gov/search/intervention=laquinimod Entries in NIH Study Registry]
Wikimedia Foundation. 2010.